Skip to content

tDCS for Increasing Exercise Adherence in Depressed Individuals

tDCS for Increasing Exercise Adherence in Individuals With Elevated Depressive Symptoms

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03178903
Acronym
StRIDE
Enrollment
51
Registered
2017-06-07
Start date
2017-02-01
Completion date
2019-12-31
Last updated
2023-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Physical Activity

Brief summary

The purpose of this study is to examine the efficacy of tDCS (transcranial direct current stimulation) for increasing exercise adherence among low active individuals with elevated depressive symptoms. The investigators expect that this project will contribute much needed knowledge about the role that tDCS can play in changing the affective experience of exercise.

Detailed description

Exercise adherence is a significant public health problem. Affective experiences during exercise predict long-term physical activity (PA) levels. Therefore, approaches to improving the affective experience of exercise are both important and likely to have high impact. This may be particularly true among individuals with elevated depressive symptoms due to their tendency toward more negative and less positive affect. tDCS is a noninvasive brain stimulation approach with a growing body of literature supporting its effects on cognitive and emotional processing in varied populations, including some support for those with depression. In addition, there is recent increased interest in utilizing tDCS in the context of exercise (see above) and in obesity prevention. While the effects of tDCS on behavioral and cognitive functioning are still developing, promising findings have emerged for tDCS used in repeated combination with a behavioral or cognitive intervention. Given that tDCS is relatively safe, inexpensive, and portable, individuals who struggle with enjoying exercise could be afforded a practical option for increasing and maintaining physical activity levels. We propose to conduct a pilot randomized controlled trial of tDCS versus sham delivered 3x/week for 8 weeks in the context of a supervised aerobic exercise (AE) program among 72 low-active individuals with elevated depressive symptoms. Follow-up assessments will be conducted at end of treatment, 3, and 6 months.

Interventions

OTHERtDCS

Participants in transcranial direct current stimulation (tDCS) will receive tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks.

OTHERSham tDCS

Participants in sham transcranial direct current stimulation (tDCS) will receive shame tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks.

Participants will engage in supervised, 30-minute bouts of moderate-intensity exercise 3x/week for 8 weeks.

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Butler Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* be between 18 and 65 years of age * be low active * have elevated levels of depressive symptoms * interested in starting an exercise program in the next month

Exclusion criteria

* history of mania or hypomania * current psychotic disorder * current DSM-5 diagnosis of an eating disorder * DSM-5 moderate and severe substance use disorder * current suicidality or homicidality * current DSM-5 diagnosis of major depressive disorder that is not currently being treated with pharmacotherapy or psychotherapy * physical disabilities or medical problems that would prevent participation in moderate intensity exercise or may be contraindicated for tDCS * current pregnancy or intent to become pregnant during the next 8 weeks * pacemaker or metal implanted in the cranial cavity

Design outcomes

Primary

MeasureTime frameDescription
Physical Activity Levels8 week assessmentAccelerometry-based moderate-to-vigorous physical activity (MVPA)

Countries

United States

Participant flow

Participants by arm

ArmCount
tDCS and Aerobic Exercise
Each participant will undergo a 20-minute session of transcranial direct current stimulation (tDCS) delivered to the dorsolateral prefrontal cortex (DLPFC). Each session of tDCS will be immediately followed by a supervised 30-minute, moderate-intensity bout of exercise. These procedures will occur 3x/week for 8 weeks. tDCS: Participants in transcranial direct current stimulation (tDCS) will receive tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks. Aerobic Exercise (AE): Participants will engage in supervised, 30-minute bouts of moderate-intensity exercise 3x/week for 8 weeks.
25
Sham tDCS and Aerobic Exercise
Each participant will undergo a 20-minute session of sham transcranial direct current stimulation (tDCS) delivered to the dorsolateral prefrontal cortex (DLPFC). Each session of tDCS will be immediately followed by a supervised 30-minute, moderate-intensity bout of exercise. These procedures will occur 3x/week for 8 weeks. Sham tDCS: Participants in sham transcranial direct current stimulation (tDCS) will receive shame tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks. Aerobic Exercise (AE): Participants will engage in supervised, 30-minute bouts of moderate-intensity exercise 3x/week for 8 weeks.
26
Total51

Baseline characteristics

CharacteristictDCS and Aerobic ExerciseSham tDCS and Aerobic ExerciseTotal
Age, Continuous48.9 years
STANDARD_DEVIATION 9.7
50.1 years
STANDARD_DEVIATION 11.1
49.5 years
STANDARD_DEVIATION 10.3
Depressive Symptoms22.9 units on a scale
STANDARD_DEVIATION 10
21.8 units on a scale
STANDARD_DEVIATION 11.6
22.3 units on a scale
STANDARD_DEVIATION 10.7
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants4 Participants4 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
24 Participants20 Participants44 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants2 Participants3 Participants
Minutes of Moderate-to-Vigorous Physical Activity (MVPA)14.9 minutes per day
STANDARD_DEVIATION 11
20.0 minutes per day
STANDARD_DEVIATION 14.4
17.4 minutes per day
STANDARD_DEVIATION 13
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
1 Participants1 Participants2 Participants
Race (NIH/OMB)
More than one race
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants1 Participants2 Participants
Race (NIH/OMB)
White
23 Participants23 Participants46 Participants
Region of Enrollment
United States
25 participants26 participants51 participants
Sex: Female, Male
Female
23 Participants21 Participants44 Participants
Sex: Female, Male
Male
2 Participants5 Participants7 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 250 / 26
other
Total, other adverse events
2 / 251 / 26
serious
Total, serious adverse events
4 / 250 / 26

Outcome results

Primary

Physical Activity Levels

Accelerometry-based moderate-to-vigorous physical activity (MVPA)

Time frame: 8 week assessment

Population: The numbers analyzed include only individuals that provided valid wear-time data on the primary outcome measure, using accelerometry. Specifically, only participants that provided 3 days of 8 hours/day valid wear time were included in the analysis of the primary outcome.

ArmMeasureValue (MEAN)Dispersion
tDCS and Aerobic ExercisePhysical Activity Levels17.4 minutes per dayStandard Deviation 9.8
Sham tDCS and Aerobic ExercisePhysical Activity Levels21.0 minutes per dayStandard Deviation 17.4
p-value: 0.87ANCOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026